US 11,883,404 B2
Preparation and composition for treatment of malignant tumors
Akihiro Miura, Tsukuba (JP); Hiroshi Sootome, Tsukuba (JP); and Junya Iwasaki, Tokushima (JP)
Assigned to Taiho Pharmaceuticals Co., Ltd., Tokyo (JP)
Filed by TAIHO PHARMACEUTICAL CO., LTD., Tokyo (JP)
Filed on Jun. 21, 2019, as Appl. No. 16/448,648.
Application 16/448,648 is a continuation in part of application No. 16/082,117, previously published as PCT/JP2017/008599, filed on Mar. 3, 2017.
Claims priority of application No. 2016-042662 (JP), filed on Mar. 4, 2016.
Prior Publication US 2019/0350932 A1, Nov. 21, 2019
Int. Cl. A61K 31/519 (2006.01); A61K 31/5383 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/5383 (2013.01); A61P 35/00 (2018.01)] 13 Claims
OG exemplary drawing
 
1. An antitumor agent comprising
a) (S)-1-(3-(4-Amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a pharmaceutically acceptable salt thereof, and
b) trans-3-amino-1-methyl-3-(4-(3-phenyl-5H-imidazo[1,2-c]pyrido[3,4-e][1,3]oxazin-2-yl)phenyl)cyclobutanol or a pharmaceutically acceptable salt thereof.